Central Hospital of Zhumadian City

Zhumadian, China

Central Hospital of Zhumadian City

Zhumadian, China
SEARCH FILTERS
Time filter
Source Type

Xia J.-H.,Zhengzhou University | Xia J.-H.,Central Hospital of Zhumadian City | He C.-H.,Zhengzhou University | Zhang H.-F.,Zhengzhou University | And 4 more authors.
International Journal of Neuroscience | Year: 2016

Aims: The aims of this study were to investigate the clinical effects and safety of botulinum toxin A (BTX-A) in treating trigeminal neuralgia and its influences on accompanied depression, anxiety, sleep disorders, and quality of life. Methods and Material: Eighty-seven patients with one-branch classical trigeminal neuralgia were injected with BTX-A in the pain area. The visual analogic scale score, sleep interference score, Hamilton Anxiety Scale score, Hamilton Depression Scale score, and side effects were assessed at 1 week prior to and 8 weeks after treatment, respectively. Results: The effective rates after 1, 2, 4, and 8 weeks of treatment were 48.28%, 66.67%, 78.16%, and 80.46%, respectively. The effective rates of anxiety and depression were 90.32% and 96.77%, respectively. When compared to that before treatment, the quality of life was significantly better in terms of role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health (all P < 0.01), while physical function was not significantly improved (P = 0.317). Conclusion: BTX-A treatment can significantly relieve the pain in trigeminal neuralgia patients; improve anxiety, depression, and sleep; and increase the quality of life. BTX-A treatment is a safe and effective method to treat classical trigeminal neuralgia. Copyright © 2015 Taylor and Francis.


Zhu X.-H.,Central Hospital of Zhumadian City
Latin American Journal of Pharmacy | Year: 2016

Human carboxyl esterase 1 (CES1) catalyzes most of administered clopidogrel which is a drug clinically used to treat ischemic heart disease and stroke. Inhibition of CES1-catalyzed hydrolysis reaction of clopidogrel will significantly increase the therapeutic role of clopidogrel. The present study aims to determine the inhibition of Fructus psoralea’s ingredients on the activity of clopidogrel hydrolysis, trying answer whether herb Fructus psoralea can increase the efficiency of clopidogrel. The in vitro system is consisted of 50 mM PBS buffer (pH = 7.4), 25 μM of clopidogrel, and 25 μg/mL of liver microsomes from human, mice and rat; 100 μM of neobavaisoflavone, corylifolinin, coryfolin, psoralidin, corylin, and bavachinin inhibited human liver microsomes (HLMs)-catalyzed hydrolysis of clopidogrel by 57.3, 46.8, 79.5, 70.3, 75, and 67.8%, respectively. For mice liver microsomes (MLMs), the activity of clopidogrel hydrolysis was inhibited by 47.4, 46.8, 13.6, 81, 74.8, and 67.1% by neobavaisoflavone, corylifolinin, coryfolin, psoralidin, corylin and bavachinin, respectively; 100 μM of neobavaisoflavone, corylifolinin, coryfolin, psoralidin, corylin and bavachinin inhibited rat liver microsomes (RLMs)-catalyzed hydrolysis of clopidogrel by 47.4, 46.8, 85.3, 41.4, 40.4, and 43.5%, respectively. In conclusion, herb-drug interaction was evaluated between Fructus psoralea and clopidogrel, and the results showed that Fructus psoralea can inhibit CES1catalyzed hydrolysis metabolism of clopidogrel, indicating the new therapeutic utilization to increase the therapeutic potential of clopidogrel. Through comparing the inhibition potential of Fructus psoralea’s ingredients on the hydrolysis of clopidogrel in mice liver microsomes and rat liver microsomes, we found that rat is more suitable animal model for investigating Fructus psoralea-clopidogrel interaction. © 2016, Colegio de Farmaceuticos de la Provincia de Buenos Aires. All rights reserved.


Liu C.,Zhengzhou University | Liu C.,Henan Province Key Laboratory of Medicine | Qin S.,Zhengzhou University | Xu H.,Zhengzhou University | And 9 more authors.
PLoS ONE | Year: 2015

The emergence of New Delhi metallo-β-lactamase 1 (NDM-1) has become established as a major public health threat and represents a new challenge in the treatment of infectious diseases. In this study, we report a high incidence and endemic spread of NDM-1-producing carbapenem-resistant Enterobacter cloacae isolates in Henan province, China. Eight (72.7%) out of eleven non-duplicated carbapenem-resistant E. cloacae isolates collected between June 2011 and May 2013 were identified as NDM-1 positive. The blaNDM-1 gene surrounded by an entire ISAba125 element and a bleomycin resistance gene bleMBL in these isolates were carried by diverse conjugatable plasmids (IncA/C, IncN, IncHI2 and untypeable) ranging from ∼55 to ∼360 kb. Molecular epidemiology analysis revealed that three NDM-1-producing E. cloacae belonged to the same multilocus sequence type (ST), ST120, two of which were classified as extensively drug-resistant (XDR) isolates susceptible only to tigecycline and colistin. The two XDR ST120 E. cloacae isolates co-harbored blaNDM-1, armA and fosA3 genes and could transfer resistance to carbapenems, fosfomycin and aminoglycosides simultaneously via a conjugation experiment. Our study demonstrated NDM-1 was the most prevalent metallo-β-lactamase (MBL) among carbapenemresistant E.cloacae isolates and identified a potential endemic clone of ST120 in Henan province. These findings highlight the need for enhanced efforts to monitor the further spread of NDM-1 and XDR ST120 E. cloacae in this region. © 2015 Liu et al.


Zhang H.,Central Hospital of Zhumadian City | Zhang H.,Huanghuai College | Wen X.,Central Hospital of Zhumadian City | Zhang Y.,Central Hospital of Zhumadian City | And 2 more authors.
Cellular Physiology and Biochemistry | Year: 2015

Background/Aims: Vitamin D status in relation to bladder carcinoma risk was still inconsistent. This study was carried out to evaluate the relationship between vitamin D status and bladder carcinoma risk through a meta-analysis approach. Methods: Pubmed, Web of Science, CNKI, and Embase were searched systemically to find eligible studies from the earliest available date to April 16, 2015. The search terms "vitamin D", "25-hydroxyvitamin D", "bladder cancer" or "bladder carcinoma" were used to retrieve relevant studies. The exposure of interest was intake of vitamin D or serum vitamin D levels, and the outcome of interest was bladder carcinoma incidence or mortality. The pooled risk ratio (RR) values and their 95%CIs were calculated through meta-analysis. Results: Seven studies with a total of 62,141 participants met the inclusion criteria and were finally included into the meta-analysis. There was no heterogeneity among those included studies (I2 = 0%, P = 0.53). The pooled RR of bladder carcinoma for the lowest category versus the highest category of vitamin D was 1.34 (95% CI 1.17-1.53, P < 0.0001). Sensitivity analysis by omitting one study by turns showed all the pooled RRs were statistically significant. Meta-analysis of 5 studies reporting outcomes of serum vitamin D levels also showed that the low serum vitamin D level was associated with increased risk of bladder carcinoma (RR = 1.32, 95%CI 1.15-1.52, P = 0.0001). No obvious risk of publication bias was observed. Conclusion: Vitamin D deficiency is associated with increased risk of bladder carcinoma in present study. © 2015 S. Karger AG, Basel.


Lv X.-L.,Central Hospital of Zhumadian City | Wang Y.,Central Hospital of Zhumadian City | Hu B.,Central Hospital of Zhumadian City | Kang L.,Central Hospital of Zhumadian City | And 2 more authors.
African Journal of Traditional, Complementary and Alternative Medicines | Year: 2016

Background: Hypoxic–ischemic encephalopathy (HIE) in perinatal condition is highly associated with mortality and several neurological disabilities. The present experiment was blueprinted to ascertain the protective efficacy of mangiferin (MF) against hypoxic–ischemic brain injury in neonatal rats. Materials and Methods: Fourth six neonatal rats (pups) were randomly separated into four groups as a sham group that received only water (control; n=12), pups exposed to Hypoxic–ischemic (HI) insult (HI group-II; n=11), pups receiving 20 (MF 20+HI-III; n=11) or 40 (MF 40+HI-IV; n=12) mg/kg b. wt of MF dissolved in water via i.p. for 7 consecutive days as pretreatment regimen before HI insult as well as one-time post treatment after HI insult. Results: MF pretreatment for seven days considerably attenuated the cerebral infarct size, edema level, lipid peroxidation (MDA), inflammatory markers (TNF-α, IL-1β, IL-6, and NF-p65 subunit) as well as greatly ameliorated the antioxidant activities of catalase (CAT), superoxide dismutase (SOD), and glutathione reductase (GSH) and thereby maintaining the redox balance. The number of viable neuronal count (nissl bodies) was exponentially increased on administration with both the dosages of MF. Both the dosages showed substantial protection against HIE, however, 40 mg of MF exhibit superior neuroprotection in equivalence with 20 mg of MF. Conclusion: The results of the present study distinctly proving the beneficial effect of MF against HIE by concomitantly improving neuronal count and antioxidant status. Hence, we recommend MF might be used for treating neonatal HIE with some standard drugs. © 2016, African Ethnomedicines Network. All rights reserved.


Zhang H.,Central Hospital of Zhumadian City | Zhang H.,Huanghuai University | Wen X.,Central Hospital of Zhumadian City | Lu X.,Central Hospital of Zhumadian City
Tumor Biology | Year: 2013

NAD(P)H:quinone oxidoreductase 1 (NQO1) rs1800566 (Pro187Ser) is a functional polymorphism which leads to a proline-to-serine amino acid substitution at codon 187 in the NQO1 protein and enzyme activity changes. NQO1 rs1800566 polymorphism was implicated to be associated with a risk of bladder cancer, but published studies showed inconclusive results. We performed a meta-analysis of nine publications with a total of 2,661 cases and 2,738 controls on the association between NQO1 rs1800566 polymorphism and risk of bladder cancer. Data were extracted from those included studies, and the pooled odds ratio (OR) with the corresponding 95 % confidence interval (95 % CI) was calculated to assess the association. We found that there was no association between NQO1 rs1800566 polymorphism and risk of bladder cancer under all four genetic models (Ser vs. Pro, OR = 1.06, 95 % CI = 0.97-1.16, P = 0.21, I 2 = 31 %; SerSer vs. ProPro, OR = 1.12, 95 % CI = 0.89-1.42, P = 0.33, I 2 = 44 %; SerSer/ProSer vs. ProPro, OR = 1.08, 95 % CI = 0.96-1.21, P = 0.20, I 2 = 27 %; SerSer vs. ProPro/ProSer, OR = 1.06, 95 % CI = 0.85-1.32, P = 0.59, I 2 = 36 %). Meta-analysis of those eight studies from Europeans also showed that there was no association between NQO1 rs1800566 polymorphism and risk of bladder cancer under all four genetic models (Ser vs. Pro, OR = 1.02, 95 % CI = 0.93-1.13, P = 0.66, I 2 = 20 %; SerSer vs. ProPro, OR = 0.99, 95 % CI = 0.75-1.30, P = 0.93, I 2 = 38 %; SerSer/ProSer vs. ProPro, OR = 1.04, 95 % CI = 0.92-1.17, P = 0.55, I 2 = 6 %; SerSer vs. ProPro/ProSer, OR = 0.98, 95 % CI = 0.75-1.28, P = 0.87, I 2 = 39 %). This meta-analysis suggests that the NQO1 rs1800566 polymorphism is not associated with a risk of bladder cancer. Further studies with larger samples are needed, especially for studies in Asians and Africans. © 2013 International Society of Oncology and BioMarkers (ISOBM).


Zhang H.-L.,Central Hospital of Zhumadian City | Zhang Y.-J.,Zhengzhou University
Tumor Biology | Year: 2013

Tumor necrosis factor alpha (TNF-α) is a multifunctional cytokine which plays an important role in the human immune response against various pathogens, and there may be a relationship between TNF-α 308 G/A polymorphism and cervical cancer risk. We performed a meta-analysis to get a systemic assessment of the association between TNF-α 308 G/A polymorphism and cervical cancer risk. Electronic searches of PubMed, Embase, and Web of Science were performed for all publications on the association between TNF-α 308 G/A polymorphism and cervical cancer risk through October 26, 2012. The pooled odds ratios (ORs) with their 95 % confidence interval (95 % CIs) were calculated to assess the association. Fifteen studies with a total of 3,743 cervical cancer cases and 4,096 controls were finally included into the meta-analysis. Overall, TNF-α 308 G/A polymorphism was significantly associated with increased risk of cervical cancer under three main genetic comparison models (A vs. G, OR 1.20, 95 % CI 1.02-1.42, P = 0.03; AA vs. GG, OR 1.31, 95 % CI 1.00-1.72, P = 0.048; AA vs. GG/GA, OR 1.30, 95 % CI 1.00-1.71, P = 0.05). Subgroup analysis by ethnicity further showed that there was a significant association between TNF-α 308 G/A polymorphism and increased risk of cervical cancer in Asians (AA vs. GG, OR 1.83, 95 % CI 1.05-3.20, P = 0.034; AA vs. GG/GA, OR 1.84, 95 % CI 1.05-3.22, P = 0.032). The meta-analysis suggests that TNF-α 308 G/A polymorphism is associated with increased risk of cervical cancer, and TNF-α 308 G/A mutant allele A is a risk factor of cervical cancer. © 2013 International Society of Oncology and BioMarkers (ISOBM).


PubMed | Central Hospital of Zhumadian City
Type: Journal Article | Journal: Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine | Year: 2013

quinone oxidoreductase 1 (NQO1) rs1800566 (Pro187Ser) is a functional polymorphism which leads to a proline-to-serine amino acid substitution at codon 187 in the NQO1 protein and enzyme activity changes. NQO1 rs1800566 polymorphism was implicated to be associated with a risk of bladder cancer, but published studies showed inconclusive results. We performed a meta-analysis of nine publications with a total of 2,661 cases and 2,738 controls on the association between NQO1 rs1800566 polymorphism and risk of bladder cancer. Data were extracted from those included studies, and the pooled odds ratio (OR) with the corresponding 95% confidence interval (95% CI) was calculated to assess the association. We found that there was no association between NQO1 rs1800566 polymorphism and risk of bladder cancer under all four genetic models (Ser vs. Pro, OR = 1.06, 95% CI = 0.97-1.16, P = 0.21, I(2) = 31%; SerSer vs. ProPro, OR = 1.12, 95% CI = 0.89-1.42, P = 0.33, I(2) = 44%; SerSer/ProSer vs. ProPro, OR = 1.08, 95% CI = 0.96-1.21, P = 0.20, I(2) = 27%; SerSer vs. ProPro/ProSer, OR = 1.06, 95% CI = 0.85-1.32, P = 0.59, I(2) = 36%). Meta-analysis of those eight studies from Europeans also showed that there was no association between NQO1 rs1800566 polymorphism and risk of bladder cancer under all four genetic models (Ser vs. Pro, OR = 1.02, 95% CI = 0.93-1.13, P = 0.66, I(2) = 20%; SerSer vs. ProPro, OR = 0.99, 95% CI = 0.75-1.30, P = 0.93, I(2) = 38%; SerSer/ProSer vs. ProPro, OR = 1.04, 95% CI = 0.92-1.17, P = 0.55, I(2) = 6%; SerSer vs. ProPro/ProSer, OR = 0.98, 95% CI = 0.75-1.28, P = 0.87, I(2) = 39%). This meta-analysis suggests that the NQO1 rs1800566 polymorphism is not associated with a risk of bladder cancer. Further studies with larger samples are needed, especially for studies in Asians and Africans.

Loading Central Hospital of Zhumadian City collaborators
Loading Central Hospital of Zhumadian City collaborators